Fingerprint
Dive into the research topics of 'A hybrid phase I-II/III clinical trial design allowing dose re-optimization in phase III'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
A hybrid phase I-II/III clinical trial design allowing dose re-optimization in phase III
Andrew G. Chapple, Peter F. Thall
Research output: Contribution to journal › Article › peer-review
9
Scopus
citations